Mutations in Met have been identi®ed in human cancer, and we have previously shown that these mutations deregulate the enzymatic activity of this tyrosine kinase receptor, thereby unleashing its oncogenic potential. Signal transduction via wild type Met has been shown to require the autophosphorylation of two tyrosine doublets; Y8,9 which functions to enhance enzymatic activity, and Y14,15 which provides docking sites for signaling molecules, and in the present investigation we examine the importance of these residues for signaling via mutationally activated Met. We ®nd that activating mutations introduced into a membrane-spanning Met receptor circumvent the normally stringent requirement for Y8,9 phosphorylation, and do so in a largely liganddependent fashion. Similarly, activating mutations introduced into a constitutively dimerized cytoplasmic form of Met (i.e. Tpr-Met) facilitate its autophosphorylation and oncogenic activity in the absence of Y8,9 phosphorylation. We also ®nd that activating mutations allow a membrane-spanning Met receptor to overcome the requirement for the Y14,15 phosphorylation in a manner which is largely ligand-independent. These ®ndings support a model whereby activating mutations stabilize an active conformation of the Met kinase via a mechanism which can function independently of Y8,9 autophosphorylation and suggest that signaling via wild type Met and mutationally activated Met may proceed through distinct pathways.
The Met tyrosine kinase is a high-anity receptor for hepatocyte growth factor/scatter factor (HGF/SF) (Bottaro et al., 1991; Naldini et al., 1991b) . Both Met and HGF/SF are expressed in numerous tissues where their expression is con®ned predominantly to cells of epithelial and mesenchymal origin, respectively (Sonnenberg et al., 1993; Stoker et al., 1987) . Signaling via this receptor-ligand pair is essential for normal murine embryological development Schmidt et al., 1995; Uehara et al., 1995) , and has been shown to aect a wide range of biological activities including angiogenesis, cellular motility, growth, invasion and morphogenic dierentiation (reviewed in Rubin et al., 1993) .
In addition to mediating a variety of normal cellular processes, deregulated Met-HGF/SF signaling may contribute to the development and spread of tumors (reviewed in Jeers et al., 1996b) . In this regard, several oncogenic forms of Met have been discovered. The TprMet oncogene is one such form of the Met receptor, and it represents the fusion of two distinct genetic loci: tpr which encodes a leucine-zipper protein ± protein dimerization motif, and met which encodes an intracellular portion of the Met receptor, including its kinase domain (Cooper et al., 1984; Park et al., 1986; Rodrigues and Park, 1993) . The resulting chimeric proteins homodimerize and transphosphorylate, thereby generating molecules possessing constitutive kinase activity and transforming ability. A second oncogenic form of Met is the native unaltered receptor itself following continual HGF/SF autocrine stimulation (reviewed in Jeers et al,. 1996b ). Finally, Met can be oncogenically activated via a number of speci®c point mutations introduced into its kinase domain. Mutations originally identi®ed in human papillary renal carcinomas were found to generate Met molecules possessing constitutive kinase activity and transforming ability (Jeers et al., 1997a; Schmidt et al., 1997) .
A large body of literature has addressed the question of Met mediated signal transduction, and on account of their importance in receptor signaling cascades (reviewed in Pawson and Scott, 1997) , much of this work has focused on identifying which of the 16 tyrosines (Y1 ± Y16) present in the intracellular domain of Met participate in signaling. In this regard, two tyrosine doublets Y8,9 and Y14,15, have been shown to be essential for Met signaling (Fixman et al., 1997; Ponzetto et al., 1996; Rodrigues and Park, 1994; Weidner et al., 1995) . Following their phosphorylation, Y8,9 function to greatly enhance the enzymatic activity of the Met receptor (Naldini et al., 1991a; Rodrigues and Park, 1994) , while Y14,15 provide docking sites for a wide array of signaling molecules (Fixman et al., 1995 (Fixman et al., , 1996 (Fixman et al., , 1997 Paio et al., 1996; Ponzetto et al., 1994) .
Although a great deal is known about signaling via Tpr-Met and wild type Met, relatively little is known about signaling via the mutationally activated Met. In the present investigation we addressed the requirement of the aforementioned tyrosine doublets (i.e. Y8,9 and Y14,15) for signaling via mutationally activated Met, and found that mutant Met is not functionally dependent on these normally crucial tyrosines.
We previously demonstrated that mutationally activated Met mediates the transformation and tumorigenicity of NIH3T3 cells (Jeers et al., 1997a) . However, for the present investigation we were concerned that the endogenous production of both Met and HGF/SF by these cells could interfere with our proposed experiments. To circumvent this problem, we employed a chimeric molecule composed of the extracellular domain of the NGF receptor (Trk) fused to the intracellular domain of Met . The wild type Trk-Met chimera has been shown to faithfully mediate Met-associated biological activities in response to NGF , and we have demonstrated that Trk-Met is converted to a transforming gene following the introduction of activating point mutations into the Met portion of the molecule (Jeers et al., 1998a,b) . Since NIH3T3 cells express neither NGF nor Trk (Cordon-Cardo et al., 1991; Klein et al., 1991) , there should be no interference by endogenously synthesized ligand or receptor molecules in this system.
To evaluate the importance of tyrosine doublets Y8,9 and Y14,15, these residues were substituted for phenylalanine (F) in the context of wild type or mutationally activated Trk-Met. [Throughout this study, mutationally activated Met will refer to a molecule possessing two independent point mutations altering leucine (L) at residue 1213 to valine (V) and methionine (M) at residue 1268 to threonine (T) (Jeers et al., 1997a) ]. Following transfection into NIH3T3 cells and Western blotting with anti-Met antibody, each construct expressed a doublet which was not present in mock-transfected cells (Figure 1a) . The high and low molecular weight species of the doublet represent mature and precursor Trk-Met protein, respectively (data not shown). Constructs containing Y8,9FF substitutions express at a higher level than those containing Y14,15FF substitutions, or no substitutions, possibly due to decreased protein turnover as a consequence of reduced kinase activity (Jeers et al., 1997b) .
When examined for focus-forming ability, the activity of wild type Trk-Met was found to be strictly dependent on the presence of exogenous ligand, whereas mutationally activated Trk-Met was strongly transforming in both the absence and presence of ligand ( Figure 2 and Table 1 ). As expected, phenylalanine substitutions at tyrosines 8,9 and 14,15 essentially abolished the transforming activity of wild type Trk-Met. In contrast, these substitutions had only limited inhibitory eects on activated Trk-Met. Thus, while activated Trk-Met generates 1150 and 1200 foci/ mg DNA in the absence and presence of ligand, respectively, activated Trk-Met possessing Y8,9FF substitutions generates 300 and 1500 foci/mg DNA and activated Trk-Met possessing Y14,15FF substitutions generates 700 and 800 foci/mg DNA when cultured in the absence and presence of ligand, respectively.
The activity of the various Trk-Met constructs was also examined in in vivo tumorigenicity assays, whereby pools of cells stably expressing the protein of interest are injected subcutaneously into the backs of athymic nude mice, which are then monitored for tumor formation. We found that cells expressing wild type Trk-Met are non-tumorigenic throughout a 2-month observation period, whereas cells expressing activated Trk-Met (with or without Y8,9FF and Y14,15FF substitutions) are highly tumorigenic (Table 1) . Cultured explants from these tumors were found to express the respective activated Trk-Met protein, thereby supporting a role for the transfected molecules in tumor induction ( Figure 1b) . Thus, while phenylalanine substitutions at tyrosines 8,9 or 14,15 functionally inactivate wild type Trk-Met, mutationally activated Trk-Met harboring these substitutions is clearly biologically active. Figure 1 Western analysis of NIH3T3 cells expressing Trk-Met mutants. (a) Cells were transiently transfected with the indicated construct in the pMex expression vector and 50 mg of cell lysate/ sample were resolved by SDS ± PAGE on a 4 ± 15% gel under non-reducing conditions, transferred to nitrocellulose, and blotted using anti-Met (upper panel) or anti-actin (lower panel) antibody. Anti-Met antibody is SP260 (Santa Cruz Biotechnology); antiactin is clone C4 (Boehringer Mannheim). Wild type Trk-Met consists of the extracellular domain of the human NGF receptor fused to the entire intracellular domain of murine Met ; activated Trk-Met harbors L1213V and M1268T mutations in the Met portion of the molecule (Jeers et al., 1997a) . Y8,9FF and Y14,15FF represent molecules in which the indicated tyrosine (Y) residues were substituted for phenylalanine (F) (Weidner et al., 1995) ;`none' indicates that no phenylalanine for tyrosine substitutions were introduced. Control cells were transfected with empty pMex vector. Products were detected using HRP-conjugated secondary antibody and ECL reagents (Amersham). Molecular mass markers are indicated on the left. (b) Subcutaneous tumors induced in athymic nude mice by cells stably expressing the indicated construct were cultured in growth media supplemented with 800 mg/ml G418 and lysates were examined by Western analysis as described above. Control cells were stably transfected with empty pMex vector and cultured in 800 mg/ml G418 prior to Western analysis We also explored the aect of activating Met mutations in the context of the Tpr-Met oncogene. As mentioned previously, Tpr-Met is a chimeric molecule resulting from the fusion of the Met kinase domain to a tpr-encoded protein ± protein dimerization motif. Tpr-Met possesses no activating point mutations in its kinase domain, but is nonetheless constitutively active and transforming on account of its ability to spontaneously homodimerize and transphosphorylate. Previous work has demonstrated the importance of autophosphorylation of tyrosines 8,9 and 14,15 for Tpr-Met activity, and we were interested in determining if activating Met mutations could overcome these requirements, as we found they could in the context of the Trk-Met receptor. To this end, we generated a mutationally activated form (L1213V/M1268T) of TprMet (with or without phenylalanine substitutions at tyrosines 8,9 and Y14,15), and compared the activity of these molecules to that of wild type Tpr-Met (with or without similar tyrosine to phenylalanine substitutions). The expression of these proteins is illustrated in Figure 3a) .
In focus-formation and in vivo tumorigenicity assays, we found that, as expected, both Y8,9FF and Y14,15FF substitutions severely impair wild type Tpr-Met activity ( Figure 4 and Table 1 ). In contrast Y8,9FF substitutions are not inhibitory in the context of mutationally activated Tpr-Met, whereas the Y14,15FF substitutions are. Cultured explants from subcutaneous tumors were found to express the respective Tpr-Met proteins, thereby supporting a role for the transfected molecules in tumor induction (Figure 3b ).
We also determined the level of autophosphorylation of various Tpr-Met molecules, and found that the Y8,9FF substitutions essentially eliminate autophosphorylation in the context of wild type Tpr-Met, but not in the context of mutationally activated Tpr-Met (Figure 3c) .
Thus, the result of both biochemical and biological assays are consistent and demonstrate that activating Met mutations can completely overcome the otherwise stringent requirement for autophosphorylation of Y8,9 in the context of the Tpr-Met molecule. A similar conclusion was reached when these tyrosines were examined in the context of the membrane-spanning Trk-Met receptor (Figure 2 and Table 1 ). In the TrkMet system, we found that activating Met mutations could partially overcome the requirement for Y8,9 autophosphorylation in the absence of ligand, and fully overcome this requirement in the presence of ligand. Therefore, dimerization mediated either by a leucinezipper motif (in the case of Tpr-Met) or by ligand (in the case of the Trk-Met receptor), is apparently necessary for the ability of the activating Met mutations to overcome Y8,9 autophosphorylation to be fully realized.
Following their phosphorylation in the context of wild type Met, the Y8,9 tyrosine doublet functions to greatly enhance the enzymatic activity of the Met receptor. Met tyrosine Y9 represents a residue which is highly conserved among receptor tyrosine kinases (Hanks, 1991) , and its substitution has been shown to impair the enzymatic and biological activity of receptors other than Met (Fantl et al., 1989; Van Der Geer and Hunter, 1991) . It has been proposed that the phosphorylation of this residue functions to stabilize the enzymatically active form of the kinase (reviewed in Weiss and Schlessinger, 1998) , and the information in the present report is thus consistent with a scenario whereby activating Met mutations functionally stabilize the active form of the kinase through a mechanism independent of Y8,9 autophosphorylation. In this scenario dimerization could continue to play an important role by facilitating the transphosphorylation of additional crucial residues, for example tyrosines which act as docking sites for signal-transducing molecules.
The Met 14,15 tyrosine doublet has been shown to provide essential docking sites for a wide array of eector molecules which mediate signaling via the wild type Met receptor. However, we now demonstrate that these tyrosines are non-essential in the context of the mutationally activated Trk-Met receptor (Figure 2 and Table 1 ). An explanation for this ®nding is that the activating mutations alter the substrate speci®city of Table 1 for additional information on focus-forming activity and Figure 1 for information on the constructs the Met kinase and facilitate the autophosphorylation of residues other than Y14,15, and the phosphorylation of a dierent repertoire of SH2-domain-containing proteins than that mediated by wild type Met. This hypothesis is strengthened by the fact that activating mutations introduced into the Kit and Ret receptor tyrosine kinases have been shown to alter substrate speci®city (Piao et al., 1996; Songyang et al., 1995) .
It is interesting that activating mutations can overcome the requirement for the autophosphorylation of the 14,15 tyrosine doublet in the context of the Trk-Met receptor, but not in the context of the TprMet oncogene (Figure 4 and Table 1 ). However, since the Trk-Met receptor (membrane-spanning) and the Tpr-Met molecule (cytoplasmic) reside in dierent cellular compartments, and may therefore interact with dierent subsets of signaling molecules, perhaps the cellular localization of Tpr-Met precludes its interaction with signaling molecules that are utilized by the activated Met receptor in overcoming the Y14,15 autophosphorylation requirement. Alternatively, it is possible that structural considerations are important in explaining our observation. For example, perhaps the region of the activated Met receptor which is instrumental in overcoming the Y14,15 requirement is obscured or missing in Tpr-Met (which encodes only Figure 3 Expression and autophosphorylation of Tpr-Met mutants in NIH3T3 cells. (a) Cells were transiently transfected with the indicated construct in the pMex expression vector and 50 mg of cell lysate/sample were resolved by SDS ± PAGE on a 4 ± 15% gel under reducing conditions, transferred to nitrocellulose, and blotted using anti-Met (upper panel) or anti-actin (lower panel) antibody. Anti-Met antibody is C28 (Santa Cruz Biotechnology); anti-actin is clone C4. Activated Tpr-Met harbors L1213V and M1268T mutations in the Met portion of the molecule. Y8,9FF and Y14,15FF represent molecules in which the indicated tyrosine residues were substituted for phenylalanine; none' indicates that no phenylalanine for tyrosine substitutions were introduced. Control cells were transfected with empty pMex vector. Products were detected using HRP-conjugated secondary antibody and ECL reagents (Amersham). Molecular mass markers are indicated on the left. (b) Subcutaneous tumors induced in athymic nude mice by cells stably expressing the indicated construct were cultured in growth media supplemented with 800 mg/ml G418 and lysates were examined by Western analysis as described above. Control cells were stably transfected with empty pMex vector and cultured in 800 mg/ml G418 prior to Western analysis. (c) Cells were transiently transfected with the indicated construct in the pMex expression vector and 500 mg of cell lysate/sample were immunoprecipitated with anti-Met (C28) antibody and examined by Western analysis as described above using anti-Met (C28) antibody (top panel) or anti-phosphotyrosine antibody (4G10; a gift of Deborah Morrison) (bottom panel). Control cells were transfected with empty pMex vector. The band appearing in all lanes of the top panel, which migrates just below Tpr-Met, is thought to represent immunoglobulin detected non-speci®cally by the secondary antibody et al., 1997a) ; Y8,9FF and Y14,15FF represent molecules in which the indicated tyrosine (Y) residues were substituted for phenylalanine (F). Trk-Met haboring a single activating mutation (M1268T) generated 440 and 1400 foci/mg DNA in the absence and presence of ligand, respectively. NIH3T3 cells transfected with the indicated constructs were scored for focus formation after 2 weeks (Jeers et al., 1997a) . Samples receiving NGF were treated with this ligand at 100 ng/ml throughout the duration of the assay. NIH3T3 cells were cotransfected with the indicated construct plus pSV 2 Neo, selected as pools of G418 (800 mg/ml)-resistant cells, and injected subcutaneously into nude mice at 1610 6 animals (Jeers et al., 1996a) . Frequency indicates the #mice with tumors/#mice injected. Latency indicates the time at which a palpable tumor was present. Animals were monitored for 2 months. The tumorigenicity assay was performed in the absence of exogenous ligand. (Jeers et al., 1998b) , and the current results reinforce this concept.
In the present investigation, we have analysed the eects of activating Met mutations in the context of Tpr-Met for the ®rst time. However, we have previously examined the eect of Y8,9FF and Y14,15FF substitutions on mutationally activated membrane-spanning Met and found that individual activating mutations could not overcome the requirement for either set of tyrosine doublet (Jeers et al., 1998b) . There are some important dierences between the previous study and the present investigation which may help to explain these apparently contradictory results. For example, in the prior study we did not examine the focus-forming activity of the various Met molecules in the presence of ligand, as we have currently done, and we now show that ligand has a strong positive eect on the ability of activating mutations to overcome Y8,9FF substitutions. Moreover, in the current study we utilized a mutationally activated Met molecule possessing two activating mutations (L1213V/M1268T), whereas in the previous investigation we determined the eect of Y8,9FF and Y14,15FF substitutions on Met molecules harboring only single activating mutations. This is important since the doubly-mutated version of Met apparently represents a fully activated, ligand-independent version of Met (Figure 2 and Table 1 ). In contrast, Met alleles harboring single activating mutations (including individual L1213V or M1268 mutations) are only partially activated, since they are ligand-responsive, and require ligand to generate the number of foci/ mg DNA attained by wild type Met in the presence of ligand [ Table 1 (legend) and Jeers et al., 1998a] .
In summary, we have shown that activating mutations enable Met signaling to be eciently transduced in the absence of autophosphorylation of tyrosine residues Y8,9 and Y14,15. This is in contrast to signaling via wild type Met which is strictly dependent on autophosphorylation of these residues. These ®ndings support a model whereby acivating mutations stabilize an active conformation of the Met kinase via a mechanism which can function independently of Y8,9 autophosphorylation. Moreover, our results suggest that signaling via mutationally activated Met may not merely represent deregulated wild type signaling, but may in fact proceed through a novel transduction pathway.
